AU8408798A - Methods and compositions for inhibiting the proinflammatory response - Google Patents

Methods and compositions for inhibiting the proinflammatory response

Info

Publication number
AU8408798A
AU8408798A AU84087/98A AU8408798A AU8408798A AU 8408798 A AU8408798 A AU 8408798A AU 84087/98 A AU84087/98 A AU 84087/98A AU 8408798 A AU8408798 A AU 8408798A AU 8408798 A AU8408798 A AU 8408798A
Authority
AU
Australia
Prior art keywords
inhibiting
compositions
methods
proinflammatory response
proinflammatory
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU84087/98A
Inventor
Jian-Jun Chen
Gary J Nabel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Michigan
Original Assignee
University of Michigan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Michigan filed Critical University of Michigan
Publication of AU8408798A publication Critical patent/AU8408798A/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1841—Transforming growth factor [TGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2510/00—Detection of programmed cell death, i.e. apoptosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU84087/98A 1997-07-17 1998-07-16 Methods and compositions for inhibiting the proinflammatory response Abandoned AU8408798A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5282997P 1997-07-17 1997-07-17
US60052829 1997-07-17
PCT/US1998/014771 WO1999003999A1 (en) 1997-07-17 1998-07-16 Methods and compositions for inhibiting the proinflammatory response

Publications (1)

Publication Number Publication Date
AU8408798A true AU8408798A (en) 1999-02-10

Family

ID=21980170

Family Applications (2)

Application Number Title Priority Date Filing Date
AU84925/98A Abandoned AU8492598A (en) 1997-07-17 1998-07-16 Methods and compositions for tumor reduction
AU84087/98A Abandoned AU8408798A (en) 1997-07-17 1998-07-16 Methods and compositions for inhibiting the proinflammatory response

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AU84925/98A Abandoned AU8492598A (en) 1997-07-17 1998-07-16 Methods and compositions for tumor reduction

Country Status (2)

Country Link
AU (2) AU8492598A (en)
WO (2) WO1999003999A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004507469A (en) * 2000-08-29 2004-03-11 バイオニケ　ライフ　サイエンシーズ　インコーポレイテッド Regulation of FAS and FASL expression
AU2009231849A1 (en) * 2008-03-31 2009-10-08 Lenticular Research Group, Llc Processes and apparatus for preventing, delaying or ameliorating one or more symptoms of presbyopia
WO2012142526A1 (en) * 2011-04-14 2012-10-18 Modiano Jaime Use of tumor fas expression to determine response to anti-cancer therapy
WO2023034796A1 (en) * 2021-08-31 2023-03-09 Yale University Cytoskeletal tension regulators and fas ligand-combination compositions and methods of treatment using the same

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4056089A (en) * 1988-07-20 1990-02-19 Amgen, Inc. Method of treating inflammatory disorders by reducing phagocyte activation
NZ256293A (en) * 1992-09-15 1997-06-24 Immunex Corp Method of treating tumour necrosis factor - mediated inflammation by use of tnf antagonist

Also Published As

Publication number Publication date
AU8492598A (en) 1999-02-10
WO1999003998A1 (en) 1999-01-28
WO1999003999A1 (en) 1999-01-28

Similar Documents

Publication Publication Date Title
HU9800439D0 (en) Pesticide compositions
SG71134A1 (en) Unsaturated copolymers processes for preparing the same and compositions containing the same
HUP0001154A3 (en) 3-piperidyl-4-oxoquinazoline derivatives and medicincal compositions containing the same
ZA987536B (en) Stanol comprising compositions.
HUP0004398A3 (en) Alpha-aryl-n-alkylnitrones and pharmaceutical compositions containing the same
IL136937A0 (en) τ-GLUTAMYL AND β-ASPARTYL CONTAINING COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
AU3063597A (en) Polyalkylphenoxyaminoalkanes and fuel compositions containing the same
ZA982796B (en) Pesticide compositions
EP1015014A4 (en) Methods and compositions for inhibiting angiogenesis
AU9781998A (en) Huchordin and uses thereof
AU2972597A (en) Compositions and uses thereof
GB9702238D0 (en) Compositions
AU9742098A (en) Autophobic hairspray compositions
IL130093A0 (en) Hexanitrohexaazaisowurtzitane compositions and explosive compositions containing the same
AU5575398A (en) Hairdye compositions
AU4876397A (en) Insecticidal compositions and methods
AU8695298A (en) Compounds and uses thereof
IL134002A0 (en) Methoximinomethyloxadiazines used as pesticides
AU8408798A (en) Methods and compositions for inhibiting the proinflammatory response
GB9608505D0 (en) Compositions processes and uses
AUPO982097A0 (en) Methods and compositions for use therein
HUP9904695A3 (en) Soaker compositions
AU8693198A (en) Compounds and uses thereof
AU9393798A (en) Genetic compositions and methods
AUPP053197A0 (en) Compositions

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase